|
- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30441
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
回复 HBVCURER 的帖子
Should be this one
J Hepatol. 2011 Jul;55(1):103-10. doi: 10.1016/j.jhep.2010.10.025. Epub 2010 Nov 23.
Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines.
Gehring AJ1, Xue SA, Ho ZZ, Teoh D, Ruedl C, Chia A, Koh S, Lim SG, Maini MK, Stauss H, Bertoletti A.
Author information
1Singapore Institute for Clinical Sciences, Agency for Science Technology and Research, Singapore.
Abstract
BACKGROUND & AIMS:
Virus-specific T cells capable of controlling HBV and eliminating hepatocellular carcinoma (HCC) expressing HBV antigens are deleted or dysfunctional in patients with chronic HBV or HBV-related HCC. The goal of this study was to determine if T cell receptor (TCR) gene transfer can reconstitute HBV-specific T cell immunity in lymphocytes of chronic HBV patients and investigate whether HCC cells with natural HBV-DNA integration can be recognized by genetically modified T cells.
METHODS:
We used vector-mediated gene transfer to introduce HLA-A2-restricted, HBV-specific TCRs into T cells of chronic HBV as well as HBV-related HCC patients.
RESULTS:
The introduced TCRs were expressed on the cell surface, evidenced by Vβ and pentamer staining. TCR transduced T cells produced IFN-γ, TNF-α, IL-2, and lysed HBV infected hepatocyte-like cell lines. Furthermore, HCC cell lines with natural HBV-DNA integration could be recognized by HBV-specific TCR-re-directed T cells.
CONCLUSIONS:
TCR re-directed HBV-specific T cells generated from PBMC of chronic HBV and HBV-related HCC patients were multifunctional and capable of recognizing HBV-infected cells and HCC tumor cells expressing viral antigens from naturally integrated HBV DNA. These genetically modified T cells could be used to reconstitute virus-specific T cell immunity in chronic HBV patients and target tumors in HBV-related HCC.
Copyright © 2010 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
应该是这个
肝脏病学杂志。 2011年7月; 55（1）：103-10。 DOI：10.1016 / j.jhep.2010.10.025。 EPUB 2010年11月23号。
工程病毒特异性T细胞靶向的HBV感染的肝细胞和肝癌细胞系。
Gehring集团AJ1，薛SA，何ZZ，赵明福研发，Ruedl C，孙家A，苏梅S，林SG，马伊尼MK，斯斯H，BERTOLETTI A.
作者信息
1Singapore临床科学研究所，局科学技术研究，新加坡。
抽象的
背景与目的：
能够控制乙肝和消除肝细胞癌（HCC）表达HBV抗原的病毒特异性T细胞被删除或不正常的慢性HBV或HBV相关的肝癌。本研究的目的是确定是否T细胞受体（TCR）基因转移可以重组HBV特异性T细胞免疫在慢性HBV患者的淋巴细胞，并调查是否肝癌细胞与天然HBV-DNA整合可以通过遗传修饰的T细胞识别。
方法：
我们使用载体介导的基因转移引入的HLA-A2限制性，HBV特异性的TCR成慢性HBV的T细胞以及HBV相关HCC患者。
结果：
所引入的TCR表达在细胞表面上，通过Vβ和五聚体染色证实。转导的T细胞产生的IFN-γ，TNF-α，IL-2，并裂解HBV感染肝细胞样细胞系。而且，HCC细胞系的天然HBV-DNA整合可以通过HBV特异性TCR的重新定向T细胞识别。
结论：
从慢性HBV和HBV相关HCC患者的PBMC产生的TCR重新定向的HBV特异性T细胞的多功能和能够识别HBV感染的细胞和肝癌的肿瘤细胞表达来自自然整合的HBV DNA病毒抗原。这些转基因的T细胞可用于重组病毒特异性T细胞免疫在慢性HBV患者和肿瘤靶HBV相关HCC。
版权所有©2010年欧洲协会为肝脏的研究。发布时间由Elsevier B.V.保留所有权利。 |
|
楼主: ivanich
发表于 2015-11-4 01:21
